"...it's probably not a perfect product space for [pharma]... [RegenMed]... will be a finite revenue stream but it will be a significant benefit for the patient."

http://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/8023566/Britains-stem-cell-pioneers-enter-the-valley-of-death-will-big-pharma-follow.html